März 16, 2026
Regulatory
When Algorithms Become Regulation
AI medical device regulation is entering a new phase. With the EU AI Act emerging alongside the MDR, manufacturers may soon face a second regulatory framework for AI‑enabled medical devices.
Part 2 of the series “The New Rules of Medtech” by Sandra Heeg, Editor-in-Chief, MedTech Media Europe.
In the first article of this series, we examined a new regulatory question raised by AI‑based medical devices: what happens when an algorithm changes after approval.
That question is no longer theoretical. Regulators are already beginning to design new frameworks to deal with it. One of the most important of these frameworks is now emerging in Europe: the EU Artificial Intelligence Act.
If the first article examined the problem AI creates for traditional medical device regulation, this second article looks at how regulators are beginning to respond.
When device regulation meets artificial intelligence
Traditional medical device regulation was designed for products whose core functionality remains relatively stable over time. Even software‑based medical devices typically follow a predictable lifecycle: development, validation, certification and post‑market surveillance.
Artificial intelligence introduces a different dynamic. AI systems rely on data‑driven models that may evolve through retraining, exposure to new clinical environments or updates to the underlying algorithms.
As discussed in the previous article, this raises a fundamental regulatory question: How do regulators oversee medical devices whose behaviour may change over time?
The EU AI Act and AI Medical Device Regulation
In Europe, the most prominent regulatory initiative addressing this challenge is the EU Artificial Intelligence Act. The AI Act introduces a horizontal, risk‑based regulatory framework for artificial intelligence across multiple industries.
AI systems used in medical devices are generally classified as high‑risk AI systems, meaning developers must comply with specific governance and risk‑management requirements.
Among the most relevant provisions for medtech manufacturers are:
Article 9 – Risk management systems
Article 10 – Data governance and data quality requirements
Article 13 – Transparency and information requirements
Article 14 – Human oversight of AI systems
A second regulatory layer for AI devices
For manufacturers of AI‑enabled medical devices, this creates an important structural shift. Devices will still need to comply with the Medical Device Regulation (MDR).
At the same time, manufacturers may also need to demonstrate compliance with AI‑specific regulatory obligations related to dataset governance, algorithm transparency, human oversight mechanisms and lifecycle monitoring of AI behaviour.
In practice, this means that AI‑based medical devices may soon operate under two overlapping regulatory frameworks.
Implications for certification
One practical question concerns the role of notified bodies. If AI‑specific requirements become part of the regulatory landscape, notified bodies may need to integrate new forms of assessment into existing MDR conformity procedures.
The growing importance of data governance in AI medical devices
AI systems depend heavily on the quality of the datasets used for training and validation. Poor dataset design or insufficient diversity may lead to algorithmic bias or unexpected performance variations across patient populations.
Lifecycle monitoring for AI medical devices
For regulators, evaluating an AI system at the time of approval may no longer be sufficient. Increasingly, regulatory frameworks emphasize post‑market monitoring of AI performance, algorithm change management and continuous evaluation of model behaviour.
Why this matters for medtech companies
For many medtech companies, AI regulation is still treated primarily as a compliance issue. But the implications are broader, affecting software architecture, data pipelines, validation strategies and product lifecycle planning.
A new phase of medtech regulation
When the MDR entered into force in Europe, it fundamentally reshaped the regulatory landscape for medical device manufacturers. AI regulation may represent a similar turning point.
Artificial intelligence is therefore not only transforming medical technology — it is also beginning to transform how medical technology is regulated.
Author: Sandra Heeg
© 2026 Sandra Heeg. All rights reserved. Copyright retained by the author. Publication on medtechmediaeurope.com is permitted by the author and may be withdrawn at any time.